Ofatumumab in Breast Milk: A Study for Lactating Women with MS

We are examining how much ofatumumab is found in the breast milk of mothers with relapsing multiple sclerosis. This research will help us understand the safety and effects on breastfeeding infants.

1-2 years 6-10 visits Monitoring phase (IV)No Placebo Partially Remote Standard Medicines InjectionGynecology and ObstetricsNeurology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Kesimpta

Kesimpta is a medicine used to treat relapsing forms of multiple sclerosis to reduce relapses and slow disability.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Ofatumumab

Ofatumumab is a lab-made antibody that targets and reduces certain immune B cells to treat relapsing multiple sclerosis and some blood cancers.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Hospices Civils De Lyon

1000: Neurology

Bron, France

Les Hopitaux Universitaires De Strasbourg

1003: Neurology

Eckbolsheim, France

Centre Hospitalier Universitaire De Rennes

1002: Neurology

Rennes, France

Sponsor: Novartis Pharma AG

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.